David Thompson, M.A., M.S., Ph.D.
Senior Vice President
Chief Scientific Officer
David Thompson joined Inozyme Pharma as Senior Vice President and Chief Scientific Officer in April 2018. He brings to Inozyme Pharma more than 30 years of experience designing and leading research and development programs focused on bone disorders and phosphate regulation. In his newly created position at Inozyme Pharma, Dr. Thompson is responsible for scientific research as the company builds its proprietary pipeline of investigational therapies.
Prior to joining Inozyme Pharma, Dr. Thompson held executive positions in clinical research and drug development for multiple biopharma companies, including Alexion Pharmaceuticals, where he led the clinical development of asfotase alfa for the treatment of hypophosphatasia; and Pfizer, where he oversaw the osteoporosis research and frailty discovery groups. While at Merck Research Labs, Dr. Thompson conducted preclinical work and participated in the early clinical development of alendronate for the treatment of osteoporosis.
Most recently, he was a founder and president of Azure Biotech, Inc., where he was responsible for the development of a novel formulation of lasofoxifene, a non-steroidal selective estrogen receptor modulator used for the prevention and treatment of osteoporosis and the treatment of vaginal atrophy. Dr. Thompson received his M.A. from the University of Montana and both his M.S. and Ph.D. from the University of Connecticut.